TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical reported a mid-term net profit attributable to shareholders of 78.326 million yuan, a year-on-year decrease of 77.16%.
Tianjin Development (00882) announced the financial results of Livzon Pharmaceutical for the six months ending June 30, 2026, with total operating income of 642 million yuan (RMB, the same below), a year-on-year decrease of 12.29%; net profit attributable to the owners of the parent company was 78.326 million yuan, a year-on-year decrease of 77.16%; basic earnings per share were 0.25 yuan.
TIANJIN DEV (00882) announced the financial performance of Tianjin Lisheng Pharmaceutical for the six months ending June 30, 2026, with total operating revenue of 642 million yuan (RMB, the same below), a year-on-year decrease of 12.29%; net profit attributable to the parent company's owners was 78.326 million yuan, a year-on-year decrease of 77.16%; basic earnings per share were 0.25 yuan.
Related Articles
CONTEL (01912): Zhuang Jiayi and Lee Byungduck appointed as executive directors
BRII-B (02137) released its interim results, showing a loss attributable to shareholders of 101 million yuan, a year-on-year narrowing of 32.08%.
Discount retail resilience highlighted! Ross Stores, Inc. (ROST.US) has raised its annual profit forecast twice, and same-store sales have seen the longest consecutive increase in nearly five years.
CONTEL (01912): Zhuang Jiayi and Lee Byungduck appointed as executive directors
BRII-B (02137) released its interim results, showing a loss attributable to shareholders of 101 million yuan, a year-on-year narrowing of 32.08%.
Discount retail resilience highlighted! Ross Stores, Inc. (ROST.US) has raised its annual profit forecast twice, and same-store sales have seen the longest consecutive increase in nearly five years.
RECOMMEND
